Purpose. Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP ...

Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms.

Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and/or precipitate withdrawal symptoms.

(NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy ... BMB-201's efficacy suggests that it may provide better pain ...

Nalbuphine is a mixed agonist/antagonist opioid modulator. Specifically, it acts as a moderate-efficacy partial agonist or antagonist of the μ-opioid receptor (MOR) and as a high-efficacy partial ...

Employing a nurse care manager to work with patients who have an opioid addiction and prescribing partial or full opioid agonists can help more people enter treatment in primary care settings ...

who may not have been successful with treatment or other addiction therapies such as oral opioid agonist therapy (OAT) and other appropriate empirically supported services. The project will identify ...